Motivation and Patch Treatment for HIV-positive Smokers

NCT ID: NCT00551720

Last Updated: 2017-01-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 444 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-01-31
• Study Completion Date: 2004-12-31

Brief Summary

The purpose of this study is to develop and evaluate a brief, clinic-based smoking cessation treatment for an HIV+ population. We compared two treatments, a brief advice and follow-up plus nicotine patch treatment(Standard Care; SC) and brief advice and follow-up, nicotine patch, with the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation (Motivationally-Enhanced; ME), in a randomized controlled trial. We hypothesized that those HIV+ participants receiving the ME will demonstrate greater biochemically verified smoking abstinence rates at 6-month follow-up than those receiving the SC control treatment. All study participants were offered use of the nicotine patch.

Detailed Description

Cigarette smoking is highly prevalent among HIV+ individuals, posing unique health risks, impacting HAART-therapy effectiveness, and possibly altering the course of the disease. To our knowledge, Motivation and Patch Treatment for HIV-Positive Individuals (Positive PATHS) was the first NIH-funded smoking cessation intervention designed to motivate HIV+ smokers to quit. Participants were referred by physicians at eight Immunology clinics in New England and randomized to receive either a brief, two-session intervention (Standard Care; SC) modeled on PHS guidelines, or a more intensive, four-session motivational counseling intervention (Motivational-Enhancement; ME). All physicians participating in the trial were trained in study eligibility criteria, as well as basic smoking cessation counseling strategies (based on the PHS guidelines). Interested individuals were then referred to the study, with a study researcher explaining the details of the study and obtaining informed consent. Participants were then assisted in completing baseline assessments via laptop computer, and then randomized to receive either a brief intervention (2-sessions) designed to reflect the standard of care in outpatient hospital settings and modeled on PHS guidelines (standard care; SC) or a more intensive (4-session) motivational counseling intervention (motivational enhancement; ME), with both interventions providing 8-weeks of nicotine replacement (patches; NRT) to those participants willing to set a quit date. Follow-up assessments, including biochemical verification of self-reported quitters (via carbon monoxide measurement) were conducted at 2, 4, and 6 months from baseline. This study is among the first to examine the health effects of a delivered smoking cessation intervention to an HIV+ population, with the results having implications for treatments in clinical care settings.

Conditions

HIV Infections; Smoking Cessation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard Care

Group Type: EXPERIMENTAL

Standard Care

Intervention Type: BEHAVIORAL

Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch

Motivational Enhancement

Group Type: EXPERIMENTAL

Motivational Enhancement

Intervention Type: BEHAVIORAL

Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.

Interventions

Standard Care

Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch

Intervention Type: BEHAVIORAL

Motivational Enhancement

Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Be receiving care for HIV at one of the participating immunology clinics
• Be 18 years old or older
• Be current (past 7 days) cigarette smoker
• Speak English or Spanish

Exclusion Criteria

• Are pregnant or nursing
• Have uncontrolled hypertension
• Use other forms of tobacco like cigars or chewing tobacco or are using anything else to help with quitting smoking
• Are allergic to the nicotine patch or have a skin condition like eczema or psoriasis that makes them unable to use the patch

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role: lead

Principal Investigators

Raymond Niaura, PhD

Role: PRINCIPAL_INVESTIGATOR

Brown University-Butler Hospital

Elizabeth Lloyd-Richardson, PhD

Role: STUDY_DIRECTOR

Brown University/The Miriam Hospital

Locations

Stanley Street Treatment and Resources, Inc.

Fall River, Massachusetts, United States

Greater New Bedford Community Center

New Bedford, Massachusetts, United States

Hope Center for HIV Care, Memorial Hospital

Pawtucket, Rhode Island, United States

Rhode Island Hospital HIV Clinic

Providence, Rhode Island, United States

The Miriam Hospital Immunology Clinic

Providence, Rhode Island, United States

Countries

United States

References

Mdege ND, Shah S, Dogar O, Pool ER, Weatherburn P, Siddiqi K, Zyambo C, Livingstone-Banks J. Interventions for tobacco use cessation in people living with HIV. Cochrane Database Syst Rev. 2024 Aug 5;8(8):CD011120. doi: 10.1002/14651858.CD011120.pub3.

Reference Type: DERIVED

PMID: 39101506 (View on PubMed)

Lloyd-Richardson EE, Stanton CA, Papandonatos GD, Shadel WG, Stein M, Tashima K, Flanigan T, Morrow K, Neighbors C, Niaura R. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. Addiction. 2009 Nov;104(11):1891-900. doi: 10.1111/j.1360-0443.2009.02623.x. Epub 2009 Aug 28.

Reference Type: DERIVED

PMID: 19719796 (View on PubMed)

Other Identifiers

R01DA012344

Identifier Type: NIH

Identifier Source: org_study_id

View Link